STOCK TITAN
  1. Home
  2. News
  3. SXTPW

60 Degrees Pharmaceuticals, Inc. Warrant - SXTPW STOCK NEWS

Welcome to our dedicated page for 60 Degrees Pharmaceuticals Warrant news (Ticker: SXTPW), a resource for investors and traders seeking the latest updates and insights on 60 Degrees Pharmaceuticals Warrant stock.

60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The firm's pipeline products under development cover development programs for COVID-19, fungal, tick-borne, and other viral diseases.

Recent achievements include their Chief Executive Officer, Geoff Dow, PhD, planning a clinical trial to study the use of tafenoquine in treating human babesiosis, a tick-borne disease. The Company has been focused on developing new medicines for rare infectious diseases and collaborating with renowned research organizations in the U.S., Australia, and Singapore.

Financially, 60 Degrees Pharmaceuticals recently reported results for the first fiscal quarter of 2024, showcasing a strong commitment to advancing treatments for infectious diseases.

News

60 Degrees Pharma Announces IRB Approval of Phase IIA Study to Evaluate Tafenoquine for Babesiosis, an Emerging Tick-Borne Disease; Type C Meeting Re-Scheduled by FDA to January 17, 2024

Rhea-AI Summary
60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) announced the Investigational Review Board (IRB) approval for a Phase IIA clinical study to investigate tafenoquine for the treatment of hospitalized babesiosis patients. The previously announced Type C meeting with the FDA has been rescheduled to January 17, 2024, due to a federal holiday.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
acquisition clinical trial
-
News

60 Degrees Pharma Announces Type C Meeting with FDA to Discuss Development of Tafenoquine for Babesiosis, an Emerging Tick-Borne Disease

Rhea-AI Summary
60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) announced a Type C meeting with the FDA to discuss a proposed Phase II study of tafenoquine for the treatment of babesiosis, a life-threatening parasitic disease transmitted by ticks. The meeting is scheduled for January 15, 2024. Tafenoquine is currently approved for malaria prophylaxis but not for babesiosis treatment. The Company plans to conduct a clinical study to evaluate its use for this purpose.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
acquisition
-
News

60 Degrees Pharma to Present Review of Safety, Efficacy Data of 8-Aminoquinolines for Malaria and Babesiosis Treatment at ILADS Annual Scientific Meeting in Boston

Rhea-AI Summary
60 Degrees Pharmaceuticals will present scientific poster on new, long-term safety data on the use of tafenoquine for malaria prevention at the ILADS 2023 annual scientific meeting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
News

60 Degrees Pharmaceuticals Suspends Phase IIB Study of Tafenoquine for COVID-19, Pivots to Refocus on Commercialization of Treatments for Malaria and Tick-Borne Diseases

Rhea-AI Summary
60 Degrees Pharmaceuticals focuses on commercialization of ARAKODA® and plans Phase IIA study of tafenoquine for babesiosis
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial covid-19
-
News

60 Degrees Pharma Withdraws COVID Phase IIB IND, Will Resubmit Pending Assessment of Ability to Meet FDA Requirements

Rhea-AI Summary
60P Australia withdraws IND for ACLR8-LR study of tafenoquine in treating COVID-19; plans to resubmit later in 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial covid-19
-
News

60 Degrees Pharmaceuticals to Participate in H.C. Wainwright 25th Annual Global Investment Conference

Rhea-AI Summary
60 Degrees Pharmaceuticals Inc. to participate in H.C. Wainwright 25th Annual Global Investment Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
News

60 Degrees Pharmaceuticals Study Results Published by New Microbes and New Infections Demonstrate Tafenoquine Exhibits Broad Spectrum Antifungal Activity

Rhea-AI Summary
60 Degrees Pharmaceuticals announces non-clinical study results showing tafenoquine exhibits broad spectrum antifungal activity against Candida spp.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News

60 Degrees Pharmaceuticals Receives Additional U.S. Patent Covering Tafenoquine for Prevention of Plasmodium Falciparum Malaria

Rhea-AI Summary
60P awarded additional U.S. patent for tafenoquine, ensuring long-term competitive position for ARAKODA in the U.S. market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News

60 Degrees Pharmaceuticals Registers ACLR8-LR, a Phase IIB Study of Tafenoquine for Treatment of COVID-19, on ClinicalTrials.gov

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial covid-19
News

60 Degrees Pharmaceuticals Awarded Canadian Patent Covering Tafenoquine for Prevention of Malaria in Malaria-Naive Subjects

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none

FAQ

What is the current stock price of 60 Degrees Pharmaceuticals Warrant (SXTPW)?

The current stock price of 60 Degrees Pharmaceuticals Warrant (SXTPW) is $0.039 as of December 20, 2024.

What is 60 Degrees Pharmaceuticals focused on?

60 Degrees Pharmaceuticals is focused on developing new medicines for the prevention and treatment of infectious diseases.

What recent achievement did 60 Degrees Pharmaceuticals announce?

60 Degrees Pharmaceuticals announced a clinical trial to study the use of tafenoquine in treating human babesiosis.

Who is leading the efforts at 60 Degrees Pharmaceuticals?

Geoff Dow, PhD, is the Chief Executive Officer of 60 Degrees Pharmaceuticals.

Stock SXTPW logo
60 Degrees Pharmaceuticals, Inc. Warrant

Nasdaq:SXTPW

SXTPW Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

SXTPW Stock Data

1.86M
Medicinal and Botanical Manufacturing
Pharmaceutical Preparations
United States of America
WASHINGTON